Verify at source
Janoshik Analytical
Enter a verification key on the laboratory verification page.
Open verification ↗Published batch results from Janoshik Analytical. Search by product, task number, batch label, or verification key.
39 reports published
| Product | Task | Analysis date | Analysis | Verification key |
|---|---|---|---|---|
| BPC-157 + TB-500 20mg | #216066 | 2 September 2026 | BPC-157 / TB-500 blend analysis | 96FTXIJSX6A4 |
| KPV Peptide 10mg | #215320 | 31 July 2026 | KPV analysis — content and purity | NF2W9KQY4UQP |
| MOTS-c 40mg | #86684 | 7 November 2025 | Peptide vial assessment — content and purity | HK9IDSKZQWZY |
| BAC Water 3ml | #110963 | 2 March 2026 | Benzyl alcohol content | XQQ9EAULW39K |
| GHK-Cu 50mg | #204020 | 30 July 2026 | GHK-Cu analysis — content, copper and purity | EKVYHNHIBCM8 |
| RT GLP3 20mg | #204026 | 2 August 2026 | Blind GLP-1 panel — semaglutide, tirzepatide and retatrutide | CJY672179N41 |
| GLOW 70mg | #86443 | 5 November 2025 | Component content — GHK-Cu, BPC-157 and TB-500 | SLWP5WD4E2I9 |
| MOTS-c 40mg | #81070 | 1 October 2025 | Peptide vial assessment — content and purity | M573ACD1NYBI |
| GHK-Cu 50mg | #89872 | 25 November 2025 | Peptide vial assessment — content and purity | EP4QIRBYZC47 |
| BAC Water 10ml | #112277 | 3 March 2026 | pH measurement | I4T6CYSCPS1K |
| MOTS-c 10mg | #124451 | 25 March 2026 | Peptide vial assessment — content and purity | X9QFDRJ85UYG |
| RT GLP3 20mg | #165276 | 28 May 2026 | Blind GLP-1 panel — semaglutide, tirzepatide and retatrutide | FI44LWW32H9M |
| Melanotan II 10mg | #85194 | 30 October 2025 | Peptide vial assessment — content and purity | 6LU1A2YM9MN3 |
| GLOW 70mg | #85193 | 30 October 2025 | Component content — GHK-Cu, BPC-157 and TB-500 | UD6BMCBK162L |
| KLOW 80mg | #218226 | 11 August 2026 | Component identification and amount — GHK-Cu, TB-500, BPC-157 and KPV | V8BDMI927L2F |
| Tesamorelin 10mg | #85191 | 30 October 2025 | Peptide vial assessment — content and purity | 7QP6JH56B1AJ |
| BPC-157 + TB-500 20mg | #93610 | 15 December 2025 | Peptide vial assessment — content of both components | JWEF9BZILKG9 |
| ADAMAX 10mg | #99778 | 19 January 2026 | Peptide vial assessment — content and purity | PR7FPUJD2T9X |
| BPC-157 10mg | #85186 | 30 October 2025 | Peptide vial assessment — content and purity | L28LJGBST3K7 |
| CAGRILINTIDE 10mg | #86685 | 7 November 2025 | Peptide vial assessment — content and purity | J3EQW2TEZQKZ |
| CJC-1295 / IPAMORELIN 10mg | #89881 | 25 November 2025 | Component content — CJC-1295 (no DAC) and ipamorelin | AWKK8Y5EIR1V |
| GHK-CU 100mg | #215318 | 31 July 2026 | GHK-Cu analysis — content, copper and purity | FFU7FYYJNJ9V |
| IGF-1 LR3 1mg | #89869 | 25 November 2025 | Peptide vial assessment — content and purity | LB7H22VJ8JAD |
| IPAMORELIN 10mg | #86679 | 7 November 2025 | Peptide vial assessment — content and purity | T9U1LKB242MK |
| KISSPEPTIN 10mg | #165280 | 28 May 2026 | Peptide vial assessment — content and purity | ISFQN3MSA3UJ |
| MT-1 10mg | #124446 | 25 March 2026 | Peptide vial assessment — content and purity | TS39F4D23QZT |
| NAD+ 500mg | #92008 | 5 December 2025 | Qualitative and quantitative analysis | VC63IEZ7H6YF |
| PT-141 10mg | #99774 | 19 January 2026 | Peptide vial assessment — content and purity | CZRLAY7VFHQ2 |
| RT GLP3 10mg | #86681 | 7 November 2025 | Peptide vial assessment — content and purity | SKYPD9CJHB21 |
| RT GLP3 30mg | #96881 | 7 January 2026 | Peptide vial assessment — content and purity | R3NDYIU7VZ6E |
| SELANK 10mg | #86683 | 7 November 2025 | Peptide vial assessment — content and purity | 1BX5F2LVCQPD |
| SEMAX 10mg | #165292 | 28 May 2026 | Peptide vial assessment — content and purity | YC4XJNQY3USL |
| SS-31 10mg | #93612 | 15 December 2025 | Peptide vial assessment — content and purity | XLC46CAH4U1N |
| TB-500 10mg | #92009 | 8 December 2025 | Peptide vial assessment — content and purity | PDXV8UJEL1G4 |
| GLP2-TZ 10mg | #86678 | 12 November 2025 | Peptide vial assessment — content and purity | 6I2AHJIMEKP9 |
| GLP2-TZ 20mg | #93619 | 15 December 2025 | Peptide vial assessment — content and purity | JVLJT3FUFBPD |
| GLP2-TZ 30mg | #109425 | 2 March 2026 | Blind GLP-1 panel — semaglutide, tirzepatide and retatrutide | BCXU8ULHVNA7 |
| GLP2-TZ 60mg | #121369 | 16 March 2026 | Peptide vial assessment — content and purity | SIVAVHPFF6V7 |
| WOLVERINE 10mg | #85185 | 30 October 2025 | Component content — BPC-157 and TB-500 | DHS4YW44X1J6 |
Enter a verification key on the laboratory verification page.
Open verification ↗Single-compound reports include only the stated measurements. Blend reports list component results. KLOW report does not include peptide purity.
Contact Aurelius Labs with the product name and task number.
Contact ↗